2026-07-24T10:20:23-05:00 2025-12-31 930623286 ALDRICH CPAS AND ADVISORS LLP 1903 WRIGHT PLACE 180 CARLSBAD CA 92008 990 2025-01-01 460552414 CUREBOUND CURE 6193145878 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 ROBIN TOFT CHIEF EXECUTIVE OFFICER 6193145878 2026-07-16 1 DEBRA D SMITH CPA P00646873 7604318440 2026-07-16 2025 2025-03-06 01:10:19Z ROBIN TOFT 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 18863642 0 X WWW.CUREBOUND.ORG X 2012 CA MOBILIZE SAN DIEGO TO ACCELERATE CURES FOR CANCER IN OUR LIFETIME. 19 19 21 439 0 0 5672165 7968991 0 0 522299 343112 -705563 2656134 5488901 10968237 7083484 10238599 0 0 1962733 2912056 0 0 1448931 1698226 1700999 10744443 14851654 -5255542 -3883417 16440883 11857815 3522339 2822688 12918544 9035127 X CUREBOUND'S MISSION IS TO ACCELERATE CANCER RESEARCH AND SAVE LIVES. WE RAISE AND INVEST STRATEGIC FUNDING FOR INNOVATIVE ADULT AND PEDIATRIC CANCER RESEARCH WITH ONE VISION: CURES IN OUR LIFETIME. 0 0 11714338 10238599 CUREBOUND IS A COMMUNITY-POWERED CANCER RESEARCH ACCELERATOR WITH A UNIQUE FUNDING MODEL BUILT ON A CORE BELIEF THAT THE BEST IDEAS HAPPEN WHEN THE RIGHT PEOPLE WORK TOGETHER. WE UNITE TOP SCIENTISTS, PASSIONATE ADVOCATES, ENTREPRENEURS AND INVESTORS TO ADVANCE CANCER RESEARCH THAT HAS THE GREATEST OPPORTUNITY TO IMPROVE DETECTION, TREATMENT, AND SURVIVORSHIP. ALL CUREBOUND GRANTS DEMAND SCIENTIFIC COLLABORATION ACROSS INSTITUTIONS TO DRIVE RESULTS FOR PATIENTS WHO NEED IT NOW. THROUGH RIGOROUS REVIEW AND TRANSPARENCY, WE DIRECT EVERY INVESTMENT DOLLAR TOWARDS MEANINGFUL IMPACT. REPRESENTATIVE RESEARCH PARTNER INSTITUTIONS INCLUDE (BUT NOT LIMITED TO): UC SAN DIEGO MOORES CANCER CENTER, THE SALK INSTITUTE, SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, RADY CHILDREN'S HOSPITAL, SCRIPPS RESEARCH, AND LA JOLLA INSTITUTE OF IMMUNOLOGY.HEADQUARTERED IN SAN DIEGO, ONE OF THE NATION'S PREMIER HUBS FOR CANCER RESEARCH AND LIFE-SCIENCE INNOVATION, CUREBOUND CATALYZES COMPLEMENTARY STRENGTHS ACROSS BIOLOGY, TECHNOLOGY, DATA SCIENCE, AND CLINICAL NETWORKS TO ACCELERATE THE TRANSLATION OF DISCOVERY INTO CLINICAL IMPACT. CUREBOUND ALLOCATES AND ADMINISTERS RESEARCH FUNDING THROUGH FIVE GRANT MECHANISMS SPANNING DISCOVERY THROUGH CLINICAL TRANSLATION: DISCOVERY, TARGETED, CATALYST, EQUITY, CURE PRIZE. EACH OF THESE GRANT TYPES ALIGNS TO CUREBOUND'S OVERARCHING AND RESEARCH ROADMAP WITH CLEARLY DEFINED TIMELINES AND MEASURABLE MILESTONES THAT ARE TRACKED TO ACCELERATE PROGRESS. 11714338 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 24 0 21 1 0 0 0 0 0 0 0 0 0 0 0 0 X 19 19 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X CUREBOUND 6193145878 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 DONALD B KEARNS MD MMM DIRECTOR 1.00 X 0 0 0 JOHN HOOD PHD DIRECTOR 1.00 X 0 0 0 ROB SINGH DIRECTOR 1.00 X 0 0 0 HAEYOUNG TANG PHD DIRECTOR 1.00 X 0 0 0 FE WHITWORTH DIRECTOR 1.00 X 0 0 0 DAN RYAN DIRECTOR 1.00 X 0 0 0 COURT TURNER JD DIRECTOR 1.00 X 0 0 0 MARK CAFFERTY DIRECTOR 1.00 X 0 0 0 CATRIONA JAMIESON MD PHD DIRECTOR 1.00 X 0 0 0 RICH HEYMAN PHD DIRECTOR 1.00 X 0 0 0 MAGDA MARQUET PHD DIRECTOR 1.00 X 0 0 0 JULIE TAFEL KLAUS DIRECTOR 1.00 X 0 0 0 CHERYL AM ANDERSON PHD MPH MS DIRECTOR 1.00 X 0 0 0 CHRIS TRESSE DIRECTOR 1.00 X 0 0 0 LARRY BLOCH DIRECTOR 1.00 X 0 0 0 AARON DAVIS DIRECTOR 1.00 X 0 0 0 BILL KOMAN CHAIRPERSON 1.00 X 0 0 0 KAREN HOOPER CHIEF OPERATING OFFICER 40.00 X 306167 0 19818 ROBIN TOFT SECRETARY 1.00 X 0 0 0 DON ANKENY TREASURER 1.00 X 0 0 0 RICK VALENCIA VICE-CHAIR 1.00 X 0 0 0 ANNE MARBARGER CHIEF EXECUTIVE OFFICER 40.00 X 476750 0 20341 MEGAN AMBROSE CHIEF OF STAFF 40.00 X 142448 0 7343 HEATHER DEAN-PRESNALL SR. DIRECTOR, STEWARDSHIP 40.00 X 149198 0 14764 JUDITH POLHA DIRECTOR, RESEARCH & IMPACT 40.00 X 137153 0 5486 AMY MYERS SR. DIRECTOR, PHILANTHROPY 40.00 X 146937 0 2302 ERIK HANS GORDON DIRECTOR, MARKETING 40.00 X 134195 0 8106 1492848 0 78160 9 0 1 0 KATE SINCLAIR C/O 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 MARKETING/BRAND CONSULTING 216000 EZRA COHEN C/O 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 RESEARCH CONSULTANT 120000 2 5455260 2513731 1341246 7968991 343112 343112 10551539 5455260 7895405 2656134 2656134 10968237 0 0 2999246 10238599 10238599 823076 411538 205769 205769 1703341 643557 411879 647905 199643 43199 119815 36629 185996 72811 40374 72811 36797 36797 53874 53874 792339 190375 253094 348870 69355 21165 48190 35802 35108 694 161966 42391 119575 319124 39514 211017 68593 36455 36455 52322 11175 41147 18291 18291 52546 52546 DUES AND SUBSCRIPTION 31983 0 30983 1000 FOOD AND BEVERAGE 21038 21038 0 0 PARTICIPANT DIRECT EXPE 12006 141 0 11865 EQUIPMENT AND RENTAL 4158 0 0 4158 2943 496 2447 14851654 11714338 1688385 1448931 1238683 1296640 8297334 6045173 6172121 3734254 338409 154066 33806 15515 360530 612167 16440883 11857815 270843 181232 1012360 1237579 1875372 786006 363764 617871 3522339 2822688 X 6746423 5374341 6172121 3660786 12918544 9035127 16440883 11857815 -3883417 0 X 0 1 X 1 0 X 8750114 18221209 7931168 5672165 7968991 48543647 8750114 18221209 7931168 5672165 7968991 48543647 8992356 39551291 13 48 246733 522299 343112 1112205 2221926 2656134 4878060 54533912 3020838 0.72530 0.72810 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 OPERATING LEASE RIGHT-OF-USE ASSETS, NET OF ACCUMULATED AMORTIZATION 612167 612167 CURRENT PORTION OF OPERATING LEASE LIABILITIES 617871 617871 X 11139768 171531 171531 10968237 0 10968237 15023185 171531 171531 14851654 0 14851654 PART X, LINE 2: THE ORGANIZATION FOLLOWS THE PROVISIONS OF UNCERTAIN TAX POSITIONS AS ADDRESSED IN THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) ACCOUNTING STANDARDS CODIFICATION. THE ORGANIZATION RECOGNIZES ACCRUED INTEREST AND PENALTIES ASSOCIATED WITH UNCERTAIN TAX POSITIONS AS PART OF THE INCOME TAX PROVISION, WHEN APPLICABLE. THERE WERE NO AMOUNTS ACCRUED IN THE FINANCIAL STATEMENTS RELATED TO UNCERTAIN TAX POSITIONS FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024. CANCER CHALLENGE 4584225 3848631 735594 288612 114871 10959 841953 ELTON JOHN CONCERT 11422574 1606629 9815945 2218291 310913 3780000 329806 16006799 5455260 10551539 2506903 425784 3790959 1171759 7895405 2656134 1 LA JOLLA INSTITUTE FOR IMMUNOLOGY 9420 ATHENA CIRCLE LA JOLLA CA 92037 330328688 501C3 385027 0 SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. RADY CHILDREN'S HOSPITAL 3020 CHILDRENS WAY MC 5005 SAN DIEGO CA 92123 951691313 501C3 6650 0 SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. SANFORD BURNHAM PREBYS 10901 N TORREY PINES RD LA JOLLA CA 92037 510197108 501C3 1529548 0 SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. SCRIPPS RESEARCH 10550 N TORREY PINES RD LA JOLLA CA 92037 951684089 115 537267 0 SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. THE REGENTS OF UNIVERSITY OF CALIFORNIA UC SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 943067788 115 5743423 0 SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES RD LA JOLLA CA 92037 952160097 501C3 849414 0 SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. BEKEN BIO INC 1155 ISLAND AVE SUITE 100 SAN DIEGO CA 92101 851922410 250000 0 SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. RESOLUTE SCIENCE INC 3210 MERRYFIELD ROW SAN DIEGO CA 92121 852657270 250000 0 SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. ILLUDENT INC 6181 CORNERSTONE COURT EAST SUITE 104 SAN DIEGO CA 92121 821140064 250000 0 SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION 5250 CAMPANILE DRIVE SAN DIEGO CA 92182 956042721 501C3 337270 0 SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. UNIVERSITY OF ARIZONA 1401 E UNIVERSITY BLVD TUCSON AZ 85721 742652689 115 100000 0 SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. 8 3 PART I, LINE 2: CUREBOUND MAINTAINS DETAILED RECORDS TO SUBSTANTIATE THE AMOUNT OF GRANTS/ASSISTANCE AND THE SELECTION CRITERIA USED TO AWARD THE GRANTS/ASSISTANCE. THE ORGANIZATION'S ABILITY TO FUND GRANTS IS BASED ON CASH RECEIPTS IN A GIVEN CALENDAR YEAR. CUREBOUND WITHHOLDS OPERATING CAPITAL AND DISBURSES ANY EXCESS CASH TO RESEARCH GRANTS. ALL POTENTIAL GRANTEES ARE REQUIRED TO APPLY FOR RESEARCH FUNDING BY SUBMITTING SUBSTANTIAL DOCUMENTATION OF SCIENTIFIC PROCESSES AND METRICS RELATED TO THE POTENTIAL SUCCESS/OUTCOMES OF RESEARCH EFFORTS WHICH UNDERGO A SIGNIFICANT PEER-REVIEW PROCESS, FOLLOWED BY COMPREHENSIVE VETTING BY CUREBOUND'S SCIENTIFIC ADVISORY BOARD (SAB) COMPRISED OF SOME OF THE WORLD'S BEST CANCER THOUGHT LEADERS. THE SAB MAKES RECOMMENDATIONS FOR FUNDING BASED ON THE STRENGTH OF APPLICATION MATERIALS AND ALIGNMENT TO ORGANIZATIONAL RESEARCH OBJECTIVES. ONCE FUNDED, CUREBOUND REQUIRES GRANTEES TO SUBMIT PROGRESS REPORTS TO RECONCILE USE OF FUNDS AND OUTLINE ACHIEVEMENTS/EFFICACY OF RESEARCH EFFORTS. ALL CUREBOUND GRANT PROGRESS IS MONITORED AND REPORTED ANNUALLY. X X 0 0 0 0 0 0 0 1 0 ANNE MARBARGER CHIEF EXECUTIVE OFFICER 323750 0 153000 0 0 0 13470 0 6871 0 497091 0 0 0 KAREN HOOPER CHIEF OPERATING OFFICER 220500 0 85667 0 0 0 11043 0 8775 0 325985 0 0 0 HEATHER DEAN-PRESNALL SR. DIRECTOR, STEWARDSHIP 130729 0 18469 0 0 0 5989 0 8775 0 163962 0 0 0 PART I, LINE 7 ALL EMPLOYEES RECEIVED PERFORMANCE BONUSES. X 6 1341246 FMV 0 1 0 FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE FORM 990 IS PROVIDED TO EACH BOARD MEMBER FOR REVIEW BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY APPLIES TO ALL DIRECTORS AND OFFICERS OF THE ORGANIZATION, AND ANY PERSON WHO IS IN A POSITION OT EXERCISE SUBSTANTIAL INFLUENCE OVER THE DECISIONS AND AFFAIRS FO THE ORGANIZATION. ALL DIRECTORS AND OFFICERS OF THE ORGANIZATION ARE REQUIRED TO FILE AN ANNUAL DISCLOSURE STATEMENT WIT THE BOARD OF DIRECTORS. IF AN INTERESTED PERSON HAS A POSITION OF FINANCIAL INTEREST IN ANY BUSINESS OR OTHER ENTITY WITH THE CORPORATION IS CONSIDERING ENTERING INTO AN ARRANGEMENT OR TRANSACTION, THE INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER PORTION OF FINANCIAL INTEREST AND ALL MATERIAL FACTS FO THE ORGANIZATIONS BOARD OF DIRECTORS AS SOON AS THE INTERESTED PERSON HAS KNOWLEDGE OF THE POTENTIAL ARRANGEMENT OR TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF OFFICERS AND KEY EMPLOYEES ARE APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 19 ANY DOCUMENTS AS STIPULATED BY LAW ARE AVAILABLE TO THE PUBLIC UPON REQUEST.